1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Dermatology Diagnostic Devices And Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Dermatology Diagnostic Devices And Therapeutics Market, by Diagnostic Devices
8.1.1 Dermatoscopes
8.1.1.1. Market Revenue and Forecast
8.1.2. Microscopes and Trichoscopes
8.1.2.1. Market Revenue and Forecast
8.1.3. Imaging Equipment
8.1.3.1. Market Revenue and Forecast
9.1. Dermatology Diagnostic Devices And Therapeutics Market, by Application Class
9.1.1. Diagnostic Devices
9.1.1.1. Market Revenue and Forecast
9.1.2. Treatment Devices
10.1. Dermatology Diagnostic Devices And Therapeutics Market, by End Use
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
11.1. North America
11.1.1. Market Revenue and Forecast, by Diagnostic Devices
11.1.2. Market Revenue and Forecast, by Application Class
11.1.3. Market Revenue and Forecast, by End Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diagnostic Devices
11.1.4.2. Market Revenue and Forecast, by Application Class
11.1.4.3. Market Revenue and Forecast, by End Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diagnostic Devices
11.1.5.2. Market Revenue and Forecast, by Application Class
11.1.5.3. Market Revenue and Forecast, by End Use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diagnostic Devices
11.2.2. Market Revenue and Forecast, by Application Class
11.2.3. Market Revenue and Forecast, by End Use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diagnostic Devices
11.2.4.2. Market Revenue and Forecast, by Application Class
11.2.4.3. Market Revenue and Forecast, by End Use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diagnostic Devices
11.2.5.2. Market Revenue and Forecast, by Application Class
11.2.5.3. Market Revenue and Forecast, by End Use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diagnostic Devices
11.2.6.2. Market Revenue and Forecast, by Application Class
11.2.6.3. Market Revenue and Forecast, by End Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diagnostic Devices
11.2.7.2. Market Revenue and Forecast, by Application Class
11.2.7.3. Market Revenue and Forecast, by End Use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diagnostic Devices
11.3.2. Market Revenue and Forecast, by Application Class
11.3.3. Market Revenue and Forecast, by End Use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diagnostic Devices
11.3.4.2. Market Revenue and Forecast, by Application Class
11.3.4.3. Market Revenue and Forecast, by End Use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diagnostic Devices
11.3.5.2. Market Revenue and Forecast, by Application Class
11.3.5.3. Market Revenue and Forecast, by End Use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diagnostic Devices
11.3.6.2. Market Revenue and Forecast, by Application Class
11.3.6.3. Market Revenue and Forecast, by End Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diagnostic Devices
11.3.7.2. Market Revenue and Forecast, by Application Class
11.3.7.3. Market Revenue and Forecast, by End Use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diagnostic Devices
11.4.2. Market Revenue and Forecast, by Application Class
11.4.3. Market Revenue and Forecast, by End Use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diagnostic Devices
11.4.4.2. Market Revenue and Forecast, by Application Class
11.4.4.3. Market Revenue and Forecast, by End Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diagnostic Devices
11.4.5.2. Market Revenue and Forecast, by Application Class
11.4.5.3. Market Revenue and Forecast, by End Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diagnostic Devices
11.4.6.2. Market Revenue and Forecast, by Application Class
11.4.6.3. Market Revenue and Forecast, by End Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diagnostic Devices
11.4.7.2. Market Revenue and Forecast, by Application Class
11.4.7.3. Market Revenue and Forecast, by End Use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diagnostic Devices
11.5.2. Market Revenue and Forecast, by Application Class
11.5.3. Market Revenue and Forecast, by End Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diagnostic Devices
11.5.4.2. Market Revenue and Forecast, by Application Class
11.5.4.3. Market Revenue and Forecast, by End Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diagnostic Devices
11.5.5.2. Market Revenue and Forecast, by Application Class
11.5.5.3. Market Revenue and Forecast, by End Use
12.1. Canfield Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis International AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Valeant Pharmaceuticals International, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. gfa-Gevaert N.V.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Galderma S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Michelson Diagnostics Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cutera, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Genentech
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GlaxoSmithKline plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
